KYTX Kyverna Therapeutics Inc.

Price (delayed)

$7.07

Market cap

$437.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.93

Enterprise value

$437.87M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6
Highlights
Kyverna Therapeutics's quick ratio has soared by 65% YoY and by 10% from the previous quarter
Kyverna Therapeutics's EPS has increased by 20% YoY and by 10% from the previous quarter
KYTX's equity is down by 15% since the previous quarter and by 10% year-on-year

Key stats

What are the main financial stats of KYTX

KYTX stock price

How has the Kyverna Therapeutics stock price performed over time
Intraday
-5.86%
1 week
2.46%
1 month
-16.03%
1 year
12.04%
YTD
-24.79%
QTD
-20.65%

Financial performance

How have Kyverna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$158.93M
Net income
-$152.64M
Gross margin
N/A
Net margin
N/A
KYTX's operating income is up by 7% YoY and by 3% QoQ
The net income is up by 3.8% year-on-year and by 2.4% since the previous quarter

Price vs fundamentals

How does KYTX's price correlate with its fundamentals

Growth

What is Kyverna Therapeutics's growth rate over time

Valuation

What is Kyverna Therapeutics stock price valuation
P/E
N/A
P/B
2.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kyverna Therapeutics's EPS has increased by 20% YoY and by 10% from the previous quarter
KYTX's equity is down by 15% since the previous quarter and by 10% year-on-year
The price to book (P/B) is 15% higher than the last 4 quarters average of 2.4

Efficiency

How efficient is Kyverna Therapeutics business performance
The company's return on equity fell by 26% YoY
The company's return on assets fell by 14% YoY
KYTX's ROIC is up by 11% QoQ and by 5% YoY

Dividends

What is KYTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYTX.

Financial health

How did Kyverna Therapeutics financials performed over time
The current ratio has soared by 68% YoY and by 11% from the previous quarter
Kyverna Therapeutics's quick ratio has soared by 65% YoY and by 10% from the previous quarter
Kyverna Therapeutics's debt is 80% lower than its equity
KYTX's debt to equity is up by 18% QoQ
KYTX's equity is down by 15% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.